
Multiple sclerosis - Pipeline Insight, 2024
Description
Multiple sclerosis - Pipeline Insight, 2024
DelveInsight’s, “Multiple sclerosis - Pipeline Insight, 2024,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Multiple sclerosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Multiple sclerosis: Overview
Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (the brain and spinal cord).MS occurs when the immune system attacks nerve fibers and myelin sheathing (a fatty substance which surrounds/insulates healthy nerve fibers) in the brain and spinal cord. This attack causes inflammation, which destroys nerve cell processes and myelin – altering electrical messages in the brain. MS is unpredictable and affects each patient differently – some individuals may be mildly affected, while others may lose their ability to write, speak or walk.
""Multiple sclerosis - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple sclerosis pipeline landscape is provided which includes the disease overview and Multiple sclerosis treatment guidelines. The assessment part of the report embraces, in depth Multiple sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Multiple sclerosis R&D. The therapies under development are focused on novel approaches to treat/improve Multiple sclerosis.
This segment of the Multiple sclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Multiple sclerosis Emerging Drugs
- Ublituximab: TG Therapeutics
- IMU-838: Immunic
- ATA188: Atara Biotherapeutics
- ANK-700: ANOKION
Further product details are provided in the report……..
Multiple sclerosis: Therapeutic Assessment
This segment of the report provides insights about the different Multiple sclerosis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Multiple sclerosis
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Multiple sclerosis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Multiple sclerosis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Multiple sclerosis drugs.
Multiple sclerosis Report Insights
- Multiple sclerosis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Multiple sclerosis drugs?
- How many Multiple sclerosis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Multiple sclerosis?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Multiple sclerosis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Multiple sclerosis and their status?
- What are the key designations that have been granted to the emerging drugs?
- TG Therapeutics
- Immunic
- Atara Biotherapeutics
- ANOKION
- ImStem Biotechnology
- Merck Serono
- CinnaGen
- Immune Response BioPharma, Inc.
- Clene Nanomedicine
- GeNeuro SA
- Sanofi
- Bristol-Myers Squibb
- HuniLife Biotechnology, Inc.
- Emerald Health Pharmaceuticals
- Biogen
- RemeGen Co., Ltd.
- Antisense Therapeutics
- Immune Response BioPharma
- Biocad
- AB Science
- Genentech
- Novartis
- Pipeline Therapeutics
- ASLAN Pharmaceuticals
- GlaxoSmithKline
- Lucid Psycheceuticals
- Voronoi
- Hanmi Pharmaceutical
- Mapi Pharma
- f5 Therapeutics
- Autobahn Therapeutics
- AstraZeneca
- ZyVersa Therapeutics
- RedHill Biopharma
- Gossamer Bio
- Sarepta Therapeutics
- BrainStorm Cell Limited
- CytoDyn
- Pear Therapeutics
- ABION
- Ublituximab
- IMU-838
- ATA188
- ANK-700
- IMS001
- Evobrutinib
- Ocrelizumab biosimilar
- VRN-04
- NeuroVax
- GSK 3888130B
- RB 104
- Belimumab
- ABN101
- ABX 002
- Research programme: Autoimmune disorder therapeutics
- Glatiramer acetate controlled release
- Leronlimab
- Pear-006
- GB7208
- IC 100-01
- Lucid MS
- CNM-Au8
- HM 15211
- Temelimab
- SAR441344
- ASLAN 003
- PIPE 858
- ATL 1102
- Ianalumab
- 11C-BMS-986196
- Fenebrutinib
- SAR 441344
- RC18
- BIIB061
- Masitinib
- BCD-132
- HuL001
- EHP-101
- IR 902
Table of Contents
100 Pages
- Introduction
- Executive Summary
- Multiple sclerosis: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Multiple sclerosis – DelveInsight’s Analytical Perspective
- Late Stage Products (Preregistration)
- Comparative Analysis
- Ublituximab: TG Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- EHP 101: Emerald Health Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ASLAN 003: ASLAN Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Lucid MS: FSD Pharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Multiple sclerosis Key Companies
- Multiple sclerosis Key Products
- Multiple sclerosis- Unmet Needs
- Multiple sclerosis- Market Drivers and Barriers
- Multiple sclerosis- Future Perspectives and Conclusion
- Multiple sclerosis Analyst Views
- Multiple sclerosis Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.